Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ISIS 2503

Known as: ISIS-2503, ISIS2503 
A synthetic oligodeoxynucleotide. Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Phosphorothioate Oligonucleotides
gemcitabine/ISIS 2503

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Aloperine inhibits proliferation, migration and invasion and induces apoptosis by blocking the Ras signaling pathway in human breast cancer cells
Aloperine (Alo), as a quinolizidine alkaloid extracted from S. alopecuroide, has the positive activities of anti-inflammatory… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2004
Highly Cited
2004
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
PURPOSE Gemcitabine remains the standard therapy for metastatic pancreatic adenocarcinoma (ACA), but has limited activity. ISIS… Expand
2004
2004
Pharmacokinetics and Tissue Disposition in Monkeys of an Antisense Oligonucleotide Inhibitor of Ha-Ras Encapsulated in Stealth Liposomes
AbstractPurpose. This study examined the pharmacokinetics and tissue distribution of an antisense oligonucleotide ISIS 2503… Expand
Highly Cited
2003
Highly Cited
2003
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
PURPOSE The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Highly Cited
2001
Highly Cited
2001
A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
Abnormal expression of Ras proteins frequently is found with oncogenic transformation making ras a promising therapeutic target… Expand
2001
2001
Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
  • M. Morse
  • Current opinion in molecular therapeutics
  • 2001
    • Corpus ID: 7918845
ISIS-2503, a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression, is being developed by Isis Pharmaceuticals Inc as… Expand
Highly Cited
2001
Highly Cited
2001
Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
The plasma pharmacokinetics and tissue disposition of ISIS 2503 were studied in mice following single and multiple bolus… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE